Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody
442€ (200 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody
Category
Primary Antibodies
Provider
Abbexa
Reference
abx433105
Tested Applications
P-ELISA, WB
Description
PCSK9 Antibody is a Goat Polyclonal antibody against PCSK9.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Immunogen: abx269647 - C-Terminus: CRSRHLAQASQELQ |
| Host | Goat |
| Reactivity | Human |
| Assay Type | Concentration: 0.5 mg/ml |
| Recommended Dilution | P-ELISA: 1/16000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Size 1 | 200 µl |
| Form | Liquid |
| Tested Applications | P-ELISA, WB |
| Buffer | Tris saline, pH 7.3, containing 0.02% sodium azide and 0.5% bovine serum albumin. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Gene ID | 255738 |
| NCBI Accession | NP_777596.2 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Antibody anti-PCSK9 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Productos relacionados
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide is a synthetic peptide. This peptide is used in the produc…
Ver producto